The success of the Phase 3 study reverberated beyond the clinic, sending the company’s shares up more than a third in a ...
Cryptopolitan on MSN
This promising anti-aging drugs just failed its human test
One of the most studied lifespan-extending drugs in animals has just failed its test on humans in a 13-week clinical trial co ...
Kelonia is developing a next-gen blood cancer treatment that’ll reprogram T-cells to help patients’ immune systems fight ...
The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...
Investor's Business Daily on MSN
Stock market holds near highs as Intel leads chip surge; Apple, Tesla, ServiceNow in focus: Weekly review
The stock market held near highs this week as Intel and chipmakers offset ServiceNow and software woes. Apple CEO Tim Cook is leaving.
From lifestyle habits to emotional support, the absence of marriage or a partner may quietly influence cancer risk in ways we’re only beginning to understand.
GLP-1 generics enter the world’s diabetes capital and are added to bridal packages to cut ‘food noise’; can they fix India's ...
AVAI, BIOA, NAGE, LLY, and NVO Lead a New Wave of Metabolic and Molecular Anti-Aging Therapies Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio, Inc. (OTCQB: AVAI), ...
The Food and Drug Administration on Wednesday approved a new weight loss pill from drugmaker Eli Lilly. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive ...
Novo Nordisk's new Wegovy GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections. CNBC spoke with five U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results